GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Cerus Corp (NAS:CERS) » Definitions » Total Assets

Cerus (CERS) Total Assets : $189.5 Mil (As of Sep. 2024)


View and export this data going back to 1997. Start your Free Trial

What is Cerus Total Assets?

Cerus's Total Assets for the quarter that ended in Sep. 2024 was $189.5 Mil.

Warning Sign:

If a company builds assets at 20.8% a year, faster than its revenue growth rate of 15.6% over the past 5 years, it means that the company may be getting less efficient.

During the past 12 months, Cerus's average Total Assets Growth Rate was -10.10% per year. During the past 3 years, the average Total Assets Growth Rate was 14.50% per year. During the past 5 years, the average Total Assets Growth Rate was 20.80% per year. During the past 10 years, the average Total Assets Growth Rate was 19.90% per year.

During the past 13 years, Cerus's highest 3-Year average Total Assets Growth Rate was 85.10%. The lowest was -37.10%. And the median was 13.75%.

Total Assets is connected with ROA %. Cerus's annualized ROA % for the quarter that ended in Sep. 2024 was -6.26%. Total Assets is also linked to Revenue through Asset Turnover. Cerus's Asset Turnover for the quarter that ended in Sep. 2024 was 0.25.


Cerus Total Assets Historical Data

The historical data trend for Cerus's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cerus Total Assets Chart

Cerus Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 165.54 221.42 237.50 218.09 197.75

Cerus Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 205.84 197.75 189.14 185.50 189.54

Cerus Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Cerus's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Assets=Total Equity (A: Dec. 2023 )+Total Liabilities (A: Dec. 2023 )
=53.444+144.304
=197.7

Cerus's Total Assets for the quarter that ended in Sep. 2024 is calculated as

Total Assets=Total Equity (Q: Sep. 2024 )+Total Liabilities (Q: Sep. 2024 )
=54.281+135.258
=189.5

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cerus  (NAS:CERS) Total Assets Explanation

Total Assets is connected with ROA %.

Cerus's annualized ROA % for the quarter that ended in Sep. 2024 is

ROA %=Net Income (Q: Sep. 2024 )/( (Total Assets (Q: Jun. 2024 )+Total Assets (Q: Sep. 2024 ))/ count )
=-11.736/( (185.496+189.539)/ 2 )
=-11.736/187.5175
=-6.26 %

Note: The Net Income data used here is four times the quarterly (Sep. 2024) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Cerus's Asset Turnover for the quarter that ended in Sep. 2024 is

Asset Turnover
=Revenue (Q: Sep. 2024 )/( (Total Assets (Q: Jun. 2024 )+Total Assets (Q: Sep. 2024 ))/ count )
=46.017/( (185.496+189.539)/ 2 )
=46.017/187.5175
=0.25

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Cerus Total Assets Related Terms

Thank you for viewing the detailed overview of Cerus's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Cerus Business Description

Traded in Other Exchanges
Address
1220 Concord Avenue, Suite 600, Concord, CA, USA, 94520
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.
Executives
Kevin Dennis Green officer: Chief Accounting Officer C/O CERUS CORPORATION, 2411 STANWELL DRIVE, CONCORD CA 94520
Chrystal Menard officer: Chief Legal Officer C/O CERUS CORPORATION, 2550 STANWELL DRIVE, CONCORD CA 94520
Richard J Benjamin officer: Chief Medical Officer 15 WHITE PINE ROAD, NEWTON MA 02464
Hua Shan director C/O CERUS CORPORATION, 1220 CONCORD AVE., STE. 600, CONCORD CA 94520
Jami K Nachtsheim director
Swisher Daniel N Jr director C/O SUNESIS PHARMACEUTICALS, INC., 395 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO CA 94080
Frank Witney director 940 WINTER STREET, C/O PERKINELMER, WALTHAM MA 02451
William Mariner Greenman officer: President, Cerus Europe C/O CERUS CORPORATION, 2411 STANWELL DRIVE, CONCORD CA 94520
Laurence M Corash director C/O CERUS CORP, 2411 STENWELL DRIVE, CONCORD CA 94520
Vivek K Jayaraman officer: Chief Commercial Officer 3910 BRICKWAY BLVD, SANTA ROSA CA 95403
Carol Moore officer: SR. V.P. Regulatory, Clinical C/O CERUS CORPORATION, 2550 STANWELL DRIVE, CONCORD CA 94520
Eric Bjerkholt director 132 PURDURE AVENUE, KENGSINGTON CA 94708
Ann Lucena director C/O CERUS CORPORATION, 1220 CONCORD AVE. SUITE 600, CONCORD CA 94520
Gail Schulze director 3451 WELLS ROAD, MALVERN PA 19355
Timothy B Anderson director C/O JAN STERN REED BAXTER INTERNATIONAL, ONE BAXTER PARKWAY DF2 2W, DEERFIELD IL 60015